These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16411171)

  • 1. Enhanced funding of pharmacoepidemiology through patenting the disclosure of adverse event information.
    Classen JB
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):390-3. PubMed ID: 16411171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More lawyers. More bureaucrats. Less information on drug safety.
    Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):394-5. PubMed ID: 16739244
    [No Abstract]   [Full Text] [Related]  

  • 3. Patenting adverse event information: a commentary from the patent law.
    Wagner RP
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):396-7. PubMed ID: 16739247
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent holdings of US biotherapeutic companies in major markets.
    Sebastian TE; Yerram CB; Saberwal G
    Drug Discov Today; 2009 May; 14(9-10):442-5. PubMed ID: 19429502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoepidemiology].
    Hallas J; Sørensen HT
    Ugeskr Laeger; 2005 May; 167(20):2186-90. PubMed ID: 15987081
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patenting pharmaceuticals in China.
    Han W; Luo J
    Pharm Pat Anal; 2016 Jul; 5(4):249-59. PubMed ID: 27338759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase patent space visualization using chemical replacements.
    Southall NT; Ajay
    J Med Chem; 2006 Mar; 49(6):2103-9. PubMed ID: 16539399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions.
    Henz S; Maeder MT; Huber S; Schmid M; Loher M; Fehr T
    Nephrol Dial Transplant; 2008 Dec; 23(12):3939-45. PubMed ID: 18614817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Frequent drug interactions in general practice].
    Bjerrum L; Andersen M; Petersen G; Kragstrup J
    Ugeskr Laeger; 2004 Sep; 166(39):3401-4. PubMed ID: 15515394
    [No Abstract]   [Full Text] [Related]  

  • 14. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sex differences in pharmacology].
    Brøsen K
    Ugeskr Laeger; 2007 Jun; 169(25):2408-11. PubMed ID: 17594829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and patient awareness of selected potential drug interactions with self-medication.
    Indermitte J; Reber D; Beutler M; Bruppacher R; Hersberger KE
    J Clin Pharm Ther; 2007 Apr; 32(2):149-59. PubMed ID: 17381665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent border wars: defining the boundary between scientific discoveries and patentable inventions.
    Holman CM
    Trends Biotechnol; 2007 Dec; 25(12):539-43. PubMed ID: 17983675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):117-32. PubMed ID: 14998074
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):529-44. PubMed ID: 12426939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.